You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 29 No. 5, November 1973 TABLE OF CONTENTS
  Archives
  •  Online Features
  BRIEF COMMUNICATIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Central Monoamine Metabolism in Man

Effect of Putative Dopamine Receptor Agonists and Antagonists

Thomas N. Chase, MD

Arch Neurol. 1973;29(5):349-351.


Abstract

The effect of haloperidol or piribedil (ET 495) on the central metabolism of dopamine (DA) and serotonin was examined in patients with various neurologic disorders. Monoamine turnover was estimated by the rate of accumulation in lumbar spinal fluid of the principle metabolites of these suspected neuromediators during the administration of probenecid. Haloperidol, which is believed to block DA receptors, appeared to accelerate DA turnover markedly, while piribedil, a suspected DA receptor agonist, substantially reduced the turnover of this monoamine. No consistent change in serotonin metabolism attended the administration of either drug. The results suggest that studies using pharmacologic agents that act on central monoaminergic receptors may provide an important means for evaluating mechanisms for controlling monoamine synthesis in patients with central nervous system disease.



Author Affiliations

Bethesda, Md

From the Neurology Unit, National Institute of Mental Health, Bethesda, Md.


Footnotes

Accepted for publication May 22, 1973.

Read in part before the Symposium International Trivastal, Monastir, Tunisia, Dec 1, 1972.

Reprint requests to Neurology Unit, NIH Clinical Center, 9000 Rockville Pike, Bethesda, MD 20014 (Dr. Chase).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dopamine Metabolism in the Cerebrospinal Fluid of Drug-Free Schizophrenic Patients With and Without Cortical Atrophy
van Kammen et al.
Arch Gen Psychiatry 1986;43:978-983.
ABSTRACT  

Brain Dopamine Turnover and the Relief of Parkinsonism
Rinne et al.
Arch Neurol 1977;34:626-629.
ABSTRACT  

Response of Hemiballismus to Haloperidol
Gilbert
JAMA 1975;233:535-536.
ABSTRACT  

Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist
Chase et al.
Arch Neurol 1974;30:383-386.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1973 American Medical Association. All Rights Reserved.